All In Biotech

Drug Trial Radar · NCT07086326

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

A Prospective, Randomized, Open-label, Controlled Phase Ⅱ Clinical Trial of Ivonescimab Combined With Chemotherapy Versus Penpulimab Combined With Chemotherapy for Neoadjuvant Treatment of Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Jul 31, 2025

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Yang Fan, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multicenter phase II study. The trial plans to enroll 164 subjects with resectable stage IIA-IIIB (N2) NSCLC. Participants will be randomized 1:1 into either the ivonescimab plus chemotherapy or penpulimab plus chemotherapy treatment arm. After 3-4 cycles of neoadjuvant therapy, surgical resection will be performed. The primary objective is to compare the pathological complete response (pCR) rate assessed by local pathologists between ivonescimab-based and penpulimab-based chemo-immunotherapy regimens in the neoadjuvant treatment of resectable NSCLC.

Conditions

  • NSCLC
  • Neoadjuvant Therapy
  • Immunotherapy
  • AK112
  • Bispecific Antibody

Interventions

  • Ivonescimab+ChemoDrug

    Ivonescimab (AK112) + platinum-based doublet chemotherapy

  • Penpulimab+ChemoDrug

    Penpulimab (AK105) + platinum-based doublet chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Complete Response (pCR) RateTime frame: Within 1 month after surgery

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.